Cough is prevalent in patients with progressive pulmonary fibrosis (PPF) and significantly affects their quality of life.

Scientists have made a key breakthrough in treating respiratory diseases by developing a new drug delivery system that ...

Pulmonary fibrosis encompasses a spectrum of interstitial lung diseases (ILDs) characterized by chronic inflammation, aberrant tissue remodeling, and ...

Background Pulmonary hypertension (PH) is a progressive cardiopulmonary condition associated with increased morbidity and ...

Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (ILD) with a progressive pulmonary fibrosis phenotype ...

Patients with pulmonary fibrosis (PF) and pulmonary hypertension (PH) have superior transplant-free survival outcomes if they receive pulmonary vasodilator therapy in combination with antifibrotic ...

Researchers at Baylor College of Medicine and collaborating institutions have uncovered a key molecular player that is involved in lung repair and in the development of pulmonary fibrosis ...

Forced oscillation technique (FOT) can enhance early detection and management of progressive pulmonary fibrosis. Forced oscillation technique (FOT) may be a useful tool to predict the course of ...

A promising new treatment approach for idiopathic pulmonary fibrosis (IPF), a fatal and currently untreatable lung disease affecting over 3 million people globally, has been identified by Tulane ...

Researchers from the European Molecular Biology Laboratory have found that dextromethorphan, a common cough syrup ingredient, can potentially treat pulmonary fibrosis. Studies suggest it might ...

A discovery at Duke-NUS Medical School offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe.

Nerandomilast, an oral treatment being developed by Boehringer Ingelheim, bested a placebo at preserving lung function in adults with progressive pulmonary fibrosis in a Phase 3 study, according to ...